PMS-DIGOXIN TABLET

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

DIGOXIN

Disponible depuis:

PHARMASCIENCE INC

Code ATC:

C01AA05

DCI (Dénomination commune internationale):

DIGOXIN

Dosage:

0.25MG

forme pharmaceutique:

TABLET

Composition:

DIGOXIN 0.25MG

Mode d'administration:

ORAL

Unités en paquet:

250

Type d'ordonnance:

Prescription

Domaine thérapeutique:

CARDIOTONIC AGENTS

Descriptif du produit:

Active ingredient group (AIG) number: 0107281002; AHFS:

Statut de autorisation:

CANCELLED POST MARKET

Date de l'autorisation:

2016-10-28

Résumé des caractéristiques du produit

PRODUCT MONOGRAPH
Pr
pms-DIGOXIN
®
Digoxin Tablets, C.S.D. 0.0625 mg, 0.125 mg and 0.25 mg
Cardiotonic Glycoside
PHARMASCIENCE INC.
Date of Preparation:
6111 Royalmount Ave., Suite 100
July 14, 2006
Montreal, Quebec
H4P 2T4
www.pharmascience.com
Control No. 107065
Page 2 of 36
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY
PRODUCT
INFORMATION.................................................................................3
INDICATIONS
AND
CLINICAL
USE.......................................................................................3
CONTRAINDICATIONS............................................................................................................4
WARNINGS
AND
PRECAUTIONS...........................................................................................4
ADVERSE
REACTIONS
............................................................................................................8
DRUG
INTERACTIONS...........................................................................................................11
DOSAGE
AND
ADMINISTRATION.......................................................................................17
OVERDOSAGE.........................................................................................................................22
ACTION
AND
CLINICAL
PHARMACOLOGY
.....................................................................23
STORAGE
AND
STABILITY...................................................................................................28
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ......................................................28
PART II: SCIENTIFIC INFORMATION
................................................................................29
PHARMACEUTICAL
INFORMATION
..................................................................................29
CLINICAL
TRIALS
............................................................................................................